Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-Line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-Over Second-Line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy.

Trial Profile

A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-Line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-Over Second-Line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Docetaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms PARTNER
  • Sponsors Amgen
  • Most Recent Events

    • 01 Oct 2016 According to results published in the Oral Oncology Journal, the study protocol was amended which limited enrollment to patients <70 years owing to excess toxicity in older patients and added mandatory pegfilgrastim/filgrastim support.
    • 08 Jan 2014 As per the ClinicalTrials.gov rercord (NCT00454779), the planned end date has changed from 1 Dec 2012 to 1 Sep 2014.
    • 04 Jun 2013 Status changed from active, no longer recruiting to completed, according to presentation of results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top